日托儿童诺如病毒疫苗接种的成本效果分析
该研究基于疾病传播模型,分析日托儿童接种假设性诺如病毒疫苗相比现行标准照护的增量成本效果。结果显示,50%效力、200美元疫苗的ICER为7,028美元/QALY,在10万美元/QALY支付阈值下具有成本效果的概率为94.0%。结论认为即使疫苗效力中等且单价较高,日托儿童接种仍可能具有成本效果。
要点
- 50%效力疫苗可避免571.83例感染和0.003例死亡/万儿童。
- 200美元、50%效力疫苗ICER为7,028美元/QALY。
- 10万美元/QALY阈值下成本效果概率为94.0%。
核心结论
- 日托儿童诺如病毒疫苗接种即使效力中等且单价较高,仍可能具有成本效果。
- 其成本效果比与其它常规推荐儿童疫苗相似。
研究设计与样本
- 基于疾病传播模型的成本效果分析,比较日托儿童接种疫苗(90%覆盖率)加现行标准照护与单纯现行标准照护。
- 分析采用社会视角,时间跨度两年,纳入儿童医疗费用及家长生产力损失。
- 数据来源包括暴发监测数据和已发表文献。
主要发现
- 50%效力疫苗相比现行标准照护,每万名儿童避免571.83例诺如病毒病例和0.003例诺如病毒相关死亡。
- 200美元、50%效力疫苗每名儿童净成本增加178.10美元,QALY增加0.025,ICER为7,028美元/QALY。
- 概率敏感性分析显示,200美元、50%效力疫苗在10万美元/QALY支付阈值下成本效果概率为94.0%,在15万美元/QALY阈值下为95.3%。
关键数值与推荐
- 疫苗效力50%,覆盖率90%,单价200美元。
- ICER为7,028美元/QALY。
- 支付阈值10万美元/QALY时成本效果概率94.0%,15万美元/QALY时95.3%。
临床怎么用
- 为日托儿童诺如病毒疫苗接种的卫生决策提供成本效果证据参考。
- 提示即使疫苗效力中等且价格较高,接种仍可能具成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Noroviruses are the leading cause of acute gastroenteritis in the United States and outbreaks frequently occur in daycare settings. Results of norovirus vaccine trials have been promising, however there are open questions as to whether vaccination of daycare children would be cost-effective. We investigated the incremental cost-effectiveness of a hypothetical norovirus vaccination for children in daycare settings compared to no vaccination. METHODS: We conducted a model-based cost-effectiveness analysis using a disease transmission model of children attending daycare. Vaccination with a 90% coverage rate in addition to the observed standard of care (exclusion of symptomatic children from daycare) was compared to the observed standard of care. The main outcomes measures were infections and deaths averted, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). Cost-effectiveness was analyzed from a societal perspective, including medical costs to children as well as productivity losses of parents, over a two-year time horizon. Data sources included outbreak surveillance data and published literature. RESULTS: A 50% efficacious norovirus vaccine averts 571.83 norovirus cases and 0.003 norovirus-related deaths per 10,000 children compared to the observed standard of care. A $200 norovirus vaccine that is 50% efficacious has a net cost increase of $178.10 per child and 0.025 more QALYs, resulting in an ICER of $7,028/QALY. Based on the probabilistic sensitivity analysis, we estimated that a $200 vaccination with 50% efficacy was 94.0% likely to be cost-effective at a willingness-to-pay of $100,000/QALY threshold and 95.3% likely at a $150,000/QALY threshold. CONCLUSION: Due to the large disease burden associated with norovirus, it is likely that vaccinating children in daycares could be cost-effective, even with modest vaccine efficacy and a high per-child cost of vaccination. Norovirus vaccination of children in daycare has a cost-effectiveness ratio similar to other commonly recommended childhood vaccines.
引用
- Steimle LN, Havumaki J, Eisenberg MC, et al. Cost-effectiveness of pediatric norovirus vaccination in daycare settings. Vaccine. 2021. PMID: 33741192. doi:10.1016/j.vaccine.2021.02.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。